Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Zopiclone
Pinewood Laboratories Ltd
N05CF01
Zopiclone
Film-coated tablet
zopiclone
Not marketed
2024-01-05
1 PACKAGE LEAFLET 2 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT ZOPICLONE PINEWOOD 3.75 MG FILM-COATED TABLETS zopiclone READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. See section 4. The name of this medicine is Zopiclone Pinewood 3.75 mg film-coated tablets, which will be called Zopiclone Pinewood throughout this leaflet. WHAT IS IN THIS LEAFLET 1. What Zopiclone Pinewood is and what it is used for 2. What you need to know before you take Zopiclone Pinewood 3. How to take Zopiclone Pinewood 4. Possible side effects 5. How to store Zopiclone Pinewood 6. Contents of the pack and other information 1. WHAT ZOPICLONE PINEWOOD ARE AND WHAT THEY ARE USED FOR The active ingredient in these tablets is zopiclone. This belongs to a group of medicines called hypnotics. It works by acting on your brain to help you sleep. The tablets are normally used for the short-term treatment of severe sleeping difficulties in adults. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE ZOPICLONE PINEWOOD DO NOT TAKE ZOPICLONE PINEWOOD - If you are allergic to zopiclone or any of the other ingredients of this medicine (listed in section 6). - If you suffer from myasthenia gravis (a condition where the muscles easily tire and become weak) - If you have any severe breathing problems, if your lungs do not work properly (e.g. respiratory failure) - If you suffer from severe sleep apnoea syndrome - If the patient is under 18 years of age - If you suffer from severe liver problems. WARNINGS AND PRECAUTIONS Tell your doctor or pharmacist before taking Zopiclone Pinewood if any of the following app Read the complete document
Health Products Regulatory Authority 05 January 2024 CRN00D4NN Page 1 of 8 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Zopiclone Pinewood 3.75 mg film-coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 3.75mg of zopiclone. Excipient(s) with known effect Each tablet contains 16.75 mg of lactose monohydrate. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film-coated Tablet. White to off-white, round shaped, film coated tablets plain on both sides. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Short-term treatment of insomnia in adults Benzodiazepines and benzodiazepine-like agents are only indicated when the disorder is severe, disabling or subjecting the individual to extreme distress. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Treatment should be as short as possible. Generally, the duration of treatment varies from a few days to two weeks with a maximum, including tapering off of four weeks. In certain cases, extension beyond the maximum treatment period may be necessary; if so it should not take place without re- evaluation of the patient's status. The product should be taken just before retiring for the night. _Dose_ The recommended dose for adults is 7.5 mg. This dose should not be exceeded. Treatment of the elderly and patients with impaired liver function or chronic respiratory insufficiency should be initiated on a dose of 3.75 mg and if necessary increased to 7.5 mg. Although in case of renal insufficiency no accumulation of zopiclone or of its metabolites has been detected, it is recommended that patients with impaired renal function should start treatment with 3.75mg. _Paediatric population_ Zopiclone should not be used in children and adolescents aged less than 18 years. The safety and efficacy of zopiclone in children and adolescents aged less than 18 years have not been established. 4.3 CONTRAINDICATIONS Myasthenia gravis Hypersensitivity to zopiclone Severe respiratory insufficiency Severe sleep apnoea syndro Read the complete document